TIBET PHARMA(SH:600211) Zhong Guo Zheng Quan Bao·2025-09-28 20:45Core Viewpoint - Tibet Pharmaceutical is focusing on transformation and innovation, aligning with national policies, particularly in the field of innovative drugs and gene editing technology [1][3]. Group 1: Investment and Strategic Direction - Tibet Pharmaceutical plans to invest $60 million in Accuredit Therapeutics Limited, acquiring a 40.82% stake, which has been approved by the company's shareholders [1]. - The company aims to enhance its growth through both internal and external strategies, emphasizing R&D investment and project acquisition to drive sustainable development [1][2]. Group 2: Financial Performance - Over the past decade, Tibet Pharmaceutical's revenue increased from 521 million to 2.807 billion, with a compound annual growth rate (CAGR) of 18.34%, while net profit rose from 92 million to 1.051 billion, with a CAGR of 27.63% [2]. - However, in 2024, the company experienced a revenue decline of 10.45%, raising concerns about its growth sustainability, despite a 9.45% increase in net profit [2]. Group 3: Growth Strategy - To achieve sustained growth, the company must establish a second growth curve focusing on internal growth through product enhancement and external growth via R&D and acquisitions [3]. - The acquisition of Accuredit Therapeutics is seen as a critical step in the company's innovation journey, aligning with its transformation strategy [3][4]. Group 4: Gene Editing Focus - Accuredit Therapeutics, established in 2021, specializes in developing non-viral vector-based gene editing drugs and has a comprehensive technology platform [4]. - The company is currently conducting clinical trials for its lead product, ART001, which has received IND approval in both China and the U.S. [4][5]. Group 5: Safety and Market Considerations - Gene editing technology is characterized by irreversible effects, making safety a primary concern, with a typical waiting period of 2 to 5 years for clinical data to confirm safety [5]. - The company is enhancing safety through reversible gene technology and off-target detection methods [5].